Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 6/20 | 0.35 |
| ▸ | CNR2 | P34972 | 5/20 | 0.35 |
| ▸ | GLP1R | P43220 | 8/20 | 0.34 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | HTR1A | P08908 | 1/20 | 0.32 |
| ▸ | DRD2 | P14416 | 1/20 | 0.32 |
| ▸ | HTR2A | P28223 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26032095 | 0.93 | CNR1 (0.39) | CNR1CNR2SMN1; SMN2 | |
| SCHEMBL26032098 | 0.93 | CNR1 (0.39) | CNR1CNR2SMN1; SMN2 | |
| SCHEMBL26032096 | 0.86 | GLP1R (0.48) | GLP1ROPRK1 | |
| SCHEMBL26032226 | 0.82 | HPGD (0.43) | GLP1RSMN1; SMN2 | |
| SCHEMBL26032035 | 0.81 | GLP1R (0.52) | GLP1ROPRK1SMN1; SMN2 | |
| SCHEMBL26032037 | 0.81 | GLP1R (0.52) | GLP1ROPRK1SMN1; SMN2 | |
| SCHEMBL26032070 | 0.81 | GLP1R (0.52) | GLP1ROPRK1SMN1; SMN2 | |
| SCHEMBL14750406 | 0.78 | SMN1; SMN2 (0.39) | MEN1ALDH1A1KMT2ASMN1; SMN2 | |
| SCHEMBL26972994 | 0.77 | GLP1R (0.46) | GLP1ROPRK1HTR1A | |
| SCHEMBL27306806 | 0.77 | SMN1; SMN2 (0.37) | OPRK1MEN1ALDH1A1KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230265429-A1 | SKELETAL MUSCLE DELIVERY PLATFORMS AND METHODS OF USE THEREOF | Arrowhead Pharmaceuticals, Inc. | 2023-08-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230265429-A1 | SKELETAL MUSCLE DELIVERY PLATFORMS AND METHODS OF USE THEREOF | MUSK, MYLK2, TNNC1 | CNR1 4167/4885CNR2 4501/4885GLP1R 1683/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.